Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study

Koichiro Watanabe, Michael E. Thase, Toshiaki Kikuchi, Takashi Tsuboi, Yuko Asami, Elizabeth Pappadopulos, Min Zhang, Matthieu Boucher, Susan Kornstein

Research output: Contribution to journalArticle

Abstract

This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day. Failure to maintain improvement in psychosocial functioning, on the basis of the Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey, was defined as loss of at least 50% of the improvement from acute-phase baseline achieved during acute and continuation treatment or dose escalation of more than 225 mg/day. The probability of remaining well (no failure to maintain improvement in functioning) was significantly higher through 12-month maintenance treatment for patients treated with venlafaxine ER 75-225mg/day versus placebo Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey component summary scores (all P≤0.0351). Effects of up to 20 months of treatment with venlafaxine ER 75-225mg/day on psychosocial functioning were consistent with the results for venlafaxine ER 75-300mg/day.

Original languageEnglish
Pages (from-to)271-280
Number of pages10
JournalInternational Clinical Psychopharmacology
Volume32
Issue number5
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Placebos
Social Adjustment
Therapeutics
Health Surveys
Self Report
Quality of Life
Venlafaxine Hydrochloride
Major Depressive Disorder

Keywords

  • Kaplan-Meier analysis
  • Long-term care
  • Major depressive disorder
  • Treatment outcome
  • Venlafaxine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study. / Watanabe, Koichiro; Thase, Michael E.; Kikuchi, Toshiaki; Tsuboi, Takashi; Asami, Yuko; Pappadopulos, Elizabeth; Zhang, Min; Boucher, Matthieu; Kornstein, Susan.

In: International Clinical Psychopharmacology, Vol. 32, No. 5, 01.01.2017, p. 271-280.

Research output: Contribution to journalArticle

Watanabe, Koichiro ; Thase, Michael E. ; Kikuchi, Toshiaki ; Tsuboi, Takashi ; Asami, Yuko ; Pappadopulos, Elizabeth ; Zhang, Min ; Boucher, Matthieu ; Kornstein, Susan. / Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study. In: International Clinical Psychopharmacology. 2017 ; Vol. 32, No. 5. pp. 271-280.
@article{3b78a7b77c164563a9d73df5efbe7de6,
title = "Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study",
abstract = "This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day. Failure to maintain improvement in psychosocial functioning, on the basis of the Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey, was defined as loss of at least 50{\%} of the improvement from acute-phase baseline achieved during acute and continuation treatment or dose escalation of more than 225 mg/day. The probability of remaining well (no failure to maintain improvement in functioning) was significantly higher through 12-month maintenance treatment for patients treated with venlafaxine ER 75-225mg/day versus placebo Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey component summary scores (all P≤0.0351). Effects of up to 20 months of treatment with venlafaxine ER 75-225mg/day on psychosocial functioning were consistent with the results for venlafaxine ER 75-300mg/day.",
keywords = "Kaplan-Meier analysis, Long-term care, Major depressive disorder, Treatment outcome, Venlafaxine",
author = "Koichiro Watanabe and Thase, {Michael E.} and Toshiaki Kikuchi and Takashi Tsuboi and Yuko Asami and Elizabeth Pappadopulos and Min Zhang and Matthieu Boucher and Susan Kornstein",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/YIC.0000000000000183",
language = "English",
volume = "32",
pages = "271--280",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Long-term function and psychosocial outcomes with venlafaxine extended release 75-225 mg/day versus placebo in the PREVENT study

AU - Watanabe, Koichiro

AU - Thase, Michael E.

AU - Kikuchi, Toshiaki

AU - Tsuboi, Takashi

AU - Asami, Yuko

AU - Pappadopulos, Elizabeth

AU - Zhang, Min

AU - Boucher, Matthieu

AU - Kornstein, Susan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day. Failure to maintain improvement in psychosocial functioning, on the basis of the Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey, was defined as loss of at least 50% of the improvement from acute-phase baseline achieved during acute and continuation treatment or dose escalation of more than 225 mg/day. The probability of remaining well (no failure to maintain improvement in functioning) was significantly higher through 12-month maintenance treatment for patients treated with venlafaxine ER 75-225mg/day versus placebo Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey component summary scores (all P≤0.0351). Effects of up to 20 months of treatment with venlafaxine ER 75-225mg/day on psychosocial functioning were consistent with the results for venlafaxine ER 75-300mg/day.

AB - This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day. Failure to maintain improvement in psychosocial functioning, on the basis of the Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey, was defined as loss of at least 50% of the improvement from acute-phase baseline achieved during acute and continuation treatment or dose escalation of more than 225 mg/day. The probability of remaining well (no failure to maintain improvement in functioning) was significantly higher through 12-month maintenance treatment for patients treated with venlafaxine ER 75-225mg/day versus placebo Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey component summary scores (all P≤0.0351). Effects of up to 20 months of treatment with venlafaxine ER 75-225mg/day on psychosocial functioning were consistent with the results for venlafaxine ER 75-300mg/day.

KW - Kaplan-Meier analysis

KW - Long-term care

KW - Major depressive disorder

KW - Treatment outcome

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=85020670378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020670378&partnerID=8YFLogxK

U2 - 10.1097/YIC.0000000000000183

DO - 10.1097/YIC.0000000000000183

M3 - Article

VL - 32

SP - 271

EP - 280

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -